PARTHENOLIDE: SUGGESTED DRUG FOR COVID-19

被引:0
|
作者
Nemati, M. [1 ]
Pouya, F. Danesh [1 ]
Asl, E. Roshni [1 ]
Rasmi, Y. [1 ,2 ]
机构
[1] Urmia Univ Med Sci, Dept Biochem, Sch Med, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Cellular & Mol Res Ctr, Orumiyeh, Iran
来源
INFEKTSIYA I IMMUNITET | 2020年 / 10卷 / 04期
关键词
Parthenolide; COVID-19; NF-kappa B; ACTIVATION; INHIBITORS;
D O I
10.15789/2220-7619-PSD-1509
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1 beta (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.
引用
收藏
页码:789 / 791
页数:3
相关论文
共 50 条
  • [1] Cytokine storm in COVID-19 and parthenolide: Preclinical evidence
    Bahrami, Mohsen
    Kamalinejad, Mohammad
    Latifi, Seied Amirhossein
    Seif, Farhad
    Dadmehr, Majid
    PHYTOTHERAPY RESEARCH, 2020, 34 (10) : 2429 - 2430
  • [2] DNR and COVID-19: The Ethical Dilemma and Suggested Solutions
    Sultan, Hala
    Mansour, Razan
    Shamieh, Omar
    Al-Tabba, Amal
    Al-Hussaini, Maysa
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [3] Diverse Manifestations of COVID-19: Some Suggested Mechanisms
    Zaman, Md S.
    Sizemore, Robert C.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (18)
  • [4] Drug repositioning for COVID-19
    Benavides-Cordoba, Vicente
    COLOMBIA MEDICA, 2020, 51 (02):
  • [5] There is a Polish drug for Covid-19
    不详
    PRZEMYSL CHEMICZNY, 2021, 100 (11): : 1008 - 1009
  • [6] An antiviral drug for covid-19?
    Benestad, Haakon B.
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (12) : 1176 - 1176
  • [7] COVID-19 Drug Interactions
    Surmelioglu, Nursel
    Demirkan, Kutay
    JOURNAL OF CRITICAL & INTENSIVE CARE, 2020, 11 : 43 - 45
  • [8] COVID-19 Drug Development
    Kim, Seungtaek
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2022, 32 (01) : 1 - 5
  • [9] COVID-19 drug resistance
    Devi, Sharmila
    LANCET INFECTIOUS DISEASES, 2023, 23 (05): : 538 - 538
  • [10] Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19
    De Santis, Gil Cunha
    Mendrone, Alfredo
    Langhi Jr, Dante
    Covas, Dimas Tadeu
    Fabron Jr, Antonio
    Cortez, Afonso Jose Pereira
    Dinardo, Carla Luana
    Ubiali, Eugenia Maria Amorim
    Marques Jr, Jose Francisco Comenalli
    Bordin, Jose Orlando
    Rugani, Marilia Alvares
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (02) : 212 - 213